| 标题 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Oncology 作者:C. Cremolini; F. Loupakis; C. Antoniotti; C. Lupi; E. Sensi; et al 出版日期:2015-10-01 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人或该文件上传人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)